表紙
市場調查報告書

阿茲海默症(AD): 全球藥物預測與市場分析(到2028年)

Alzheimer's Disease: Global Drug Forecast and Market Analysis to 2028

出版商 GlobalData 商品編碼 940436
出版日期 內容資訊 英文 218 Pages
訂單完成後即時交付
價格
阿茲海默症(AD): 全球藥物預測與市場分析(到2028年) Alzheimer's Disease: Global Drug Forecast and Market Analysis to 2028
出版日期: 2020年05月30日內容資訊: 英文 218 Pages
簡介

全球阿茲海默症(AD)藥物市場,2018年8個主要市場(美國,歐盟五國,日本、中國)全體約為22億美金。預計在10年的預測期間內將以19.3%的年複合成長率成長,10年後達到129億美元。該市場的主要成長要素,是AD和MCI的全球盛行率增加,DMT的採用等。

本報告提供全球阿茲海默症(藥物)市場的相關調查,阿茲海默症概要和流行病學,企業和產品等的產業趨勢,各地區的市場分析等資訊。

第1章 目錄

  • 表格的清單
  • 圖的清單

第2章 摘要整理

第3章 簡介

第4章 疾病概要

  • 病因與病理學
    • 病因
    • 病理生理學
  • 病期分類系統
  • 症狀
  • 預後
  • QOL(生活品質)

第5章 流行病學

  • 疾病背景
  • 風險要素與並存症
  • 世界及過去趨勢
  • 預測調查手法
  • AD的流行病學的預測(2018年∼2028年)
  • 討論
    • 流行病學預測的洞察
    • 分析的限制
    • 分析的優勢

第6章 疾病管理

第7章 目前治療選擇

  • 概況
  • 其他治療等級

第8章 潛在的需求和機會的評估

第9章 開發平台的評估

  • 概況
  • 後期開發中產品
  • 開發中的其他藥物

第10章 現在、今後的企業

第11章 市場展望

第12章 附錄

目錄
Product Code: GDHC195PIDR

Alzheimer's disease (AD) is a progressive neurodegenerative disease that is characterized by memory loss, cognitive impairment, and functional decline. During the early stages of the disease, sleep disturbances and forgetfulness are generally the first presenting symptoms. In the severe stages, patients with AD require permanent observation, either by a home care professional or a family member. The rapidly declining status of patients with AD results in a drastic reduction in quality of life (QOL) for both patients and their caretakers. With rapidly increasing worldwide prevalence, AD has been identified as a major global health threat by the international medical community. Significant efforts have been made to develop a new treatment for AD, as current pharmacologic management is known to only provide a temporary improvement in symptoms. Without therapies that effectively stop or reverse the course of the disease, a large area of opportunity exists for the development of an effective pharmacologic approach.

The current competitive landscape in AD consists only of symptomatic treatments, of which there are currently six approved medications: three ChEIs (donepezil, rivastigmine, and galantamine), one NMDA-R antagonist (memantine), one combination therapy (memantine/donepezil), and one AB A4 protein inhibitor (sodium oligomannate). Improvements to the approved therapies, such as easier routes of administration and reduced dosing frequencies, along with the developments that are expected to occur within the next decade, could have a significant effect on the way the disease is managed. Earlier disease detection may render the currently available therapies more useful, but until disease-modifying agents are introduced, the landscape will not change significantly.

GlobalData estimates that drug sales for AD in 2018 were approximately $2.2B across the eight major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $12.9B at a CAGR of 19.3%. This growth will be driven by the increasing prevalence of AD and MCI worldwide, and the introduction of DMTs including Biogen's aducanumab, Eisai's BAN-2401, and Roche's gantenerumab. This growth will be driven by the launch of eleven late-stage pipeline products.

Key Highlights

  • Significant growth is expected in the AD market from 2018 to 2028
  • GlobalData's anticipate that eighteen late stage pipeline drugs will launch over the forecast period. These are expected to be the main driver of growth in the MS market across the 8MM.
  • GlobalData projects that Biogen's aducanumab will be one of the highest-selling DMT for AD, generating $4.2B in the 8MM in 2028.
  • There are no curative therapies for AD, and most existing DMTs only have limited efficacy on treating symptoms.
  • Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.

Key Questions Answered

  • What are the key AD treatments in 2018?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall AD market in the 8MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?

Scope

  • Overview of Alzheimer's Disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized Alzheimer's Disease therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in four patient segments (MCI, Mild, Moderate and Severe) forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the Alzheimer's Disease therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Alzheimer's Disease therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global Alzheimer's Disease therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global Alzheimer's Disease therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Alzheimer's Disease therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Executive Summary

  • 2.1 Alzheimer's Market Forecast to See Double-Digit Sales Growth out to 2028
  • 2.2 Allergan, Biogen, Eisai, and Roche Are Forecast to Lead the AD Market in 2028
  • 2.3 Lack of Treatments and Biomarkers Remain As Key Unmet Needs in the AD Market
  • 2.4 Opportunities Remain for Disease-Modifying and Symptomatic Drugs Entering the AD Market
  • 2.5 Eighteen Promising Drugs in Phase II/III or Phase III of Development
  • 2.6 What Do Physicians Think?

3 Introduction

  • 3.1 Catalyst
  • 3.2 Related Reports

4 Disease Overview

  • 4.1 Etiology and Pathophysiology
    • 4.1.1 Etiology
    • 4.1.2 Pathophysiology
  • 4.2 Disease Staging Systems
  • 4.3 Symptoms
  • 4.4 Prognosis
  • 4.5 Quality of Life

5 Epidemiology

  • 5.1 Disease Background
  • 5.2 Risk Factors and Comorbidities
  • 5.3 Global and Historical Trends
  • 5.4 Forecast Methodology
    • 5.4.1 Sources
    • 5.4.2 Forecast Assumptions and Methods
  • 5.5 Epidemiological Forecast for AD (2018-2028)
    • 5.5.1 Total Prevalent Cases of AD
    • 5.5.2 Sex-Specific Total Prevalent Cases of AD
    • 5.5.3 Age-Specific Total Prevalent Cases of AD
    • 5.5.4 Total Prevalent Cases of AD by Severity
    • 5.5.5 Diagnosed Prevalent Cases of AD
    • 5.5.6 Sex-Specific Diagnosed Prevalent Cases of AD
    • 5.5.7 Age-Specific Diagnosed Prevalent Cases of AD
    • 5.5.8 Diagnosed Prevalent Cases of AD by Severity
    • 5.5.9 Total Prevalent Cases of Mild Cognitive Impairment
    • 5.5.10 Sex-Specific Total Prevalent Cases of Mild Cognitive Impairment
    • 5.5.11 Age-Specific Total Prevalent Cases of Mild Cognitive Impairment
    • 5.5.12 Diagnosed Prevalent Cases of Mild Cognitive Impairment
    • 5.5.13 Sex-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
    • 5.5.14 Age-Specific Diagnosed Prevalent Cases of Mild Cognitive Impairment
  • 5.6 Discussion
    • 5.6.1 Epidemiological Forecast Insight
    • 5.6.2 Limitations of the Analysis
    • 5.6.3 Strengths of the Analysis

6 Disease Management

7 Current Treatment Options

  • 7.1 Overview
  • 7.2 Other Therapeutic Classes

8 Unmet Needs and Opportunity Assessment

9 Pipeline Assessment

  • 9.1 Overview
  • 9.2 Late-Stage Pipeline Products
  • 9.3 Other Drugs in Development

10 Current and Future Players

11 Market Outlook

12 Appendix

  • 1.1 List of Tables
  • Table 1: MCI and AD: Key Metrics in the 8MM
  • Table 2: Three-Stage Classification of AD
  • Table 3: The Seven-Stage Reisberg Scale of AD
  • Table 4: Common Symptoms of AD
  • Table 5: Risk Factors and Comorbidities for AD
  • Table 6: Commonly Used Diagnostic Guidelines for Alzheimer's Disease
  • Table 7: Summary of NINCDS-ARDA Diagnostic Criteria for Alzheimer's Disease
  • Table 8: Proposed NIA-AA Staging Classification for Preclinical AD
  • Table 9: NIA-AA Biomarker Criteria for MCI
  • Table 10: Commonly Used Treatment Guidelines for Alzheimer's Disease in the 8MM
  • Table 11: Most Prescribed Drugs for AD by Class in the 8MM, 2018
  • Table 12: Most Commonly Prescribed Off-Label Drug Classes for AD, by Treatment Line, in the 8MM
  • Table 13: Country Profile - US
  • Table 14: Region Profile - 5EU
  • Table 15: Country Profile - Japan
  • Table 16: Country Profile - China
  • Table 17: Leading Therapies in AD
  • Table 18: Summary of Minor Therapeutic Classes, 2020
  • Table 19: Comparison of Therapeutic Classes in Development for AD
  • Table 20: Drugs in Development for AD and AD-Related Symptoms, 2020
  • Table 21: Key Companies in the AD Market in the 8MM, 2020
  • Table 22: Allergan's AD Portfolio Assessment, 2020
  • Table 23: Lundbeck's AD Portfolio Assessment, 2020
  • Table 24: Eisai's AD Portfolio Assessment, 2020
  • Table 25: Novartis' AD Portfolio Assessment, 2020
  • Table 26: Roche's AD Portfolio Assessment, 2020
  • Table 27: Biogen's AD Portfolio Assessment, 2020
  • Table 28: Eli Lilly's AD Portfolio Assessment, 2020
  • Table 29: Takeda's AD Portfolio Assessment, 2020
  • Table 30: AD Market - Global Drivers and Barriers, 2018-2028
  • Table 31: Key Events Impacting Sales for Alzheimer's Disease in the US, 2018-2028
  • Table 32: AD Market - Drivers and Barriers in the US, 2018-2028
  • Table 33: Key Events Impacting Sales for AD in the 5EU, 2018-2028
  • Table 34: AD Market - Drivers and Barriers in the 5EU, 2018-2028
  • Table 35: Key Events Impacting Sales for AD in Japan, 2018-2028
  • Table 36: AD Market - Global Drivers and Barriers in Japan, 2018-2028
  • Table 37: Key Events Impacting Sales for AD in China, 2018-2028
  • Table 38: AD Market - Global Drivers and Barriers in China, 2018-2028
  • Table 39: Key Historical and Projected Launch Dates for AD
  • Table 40: Key Historical and Projected Patent Expiry Dates for AD
  • Table 41: High-Prescribing Physicians (non-KOLs) Surveyed, by Country
  • 1.2 List of Figures
  • Figure 1: Global Sales Forecast by Country for AD, 2018-2028
  • Figure 2: Company Portfolio Gap Analysis in AD, 2018-2028
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in AD, 2018-2028
  • Figure 4: AD Biomarker Tests by Pathophysiology
  • Figure 5: Dynamic Changes in AD Biomarker Over Time
  • Figure 6: 8MM, Total Prevalence of AD (%), Men and Women, Ages ≥60 Years, 2018
  • Figure 7: 8MM, Total Prevalence of AD (%), Men and Women, Ages ≥60 Years, 2018
  • Figure 8: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of AD Based on the DSM-IV and Clinical Criteria
  • Figure 9: 8MM, Sources Used and Not Used to Forecast the Total Prevalent Cases of MCI
  • Figure 10: 8MM, Sources Used to Forecast the Total Prevalent Cases of AD by Severity
  • Figure 11: 8MM, Total Prevalent Cases of AD, Both Sexes, Ages ≥60 Years
  • Figure 12: 8MM, Total Prevalent Cases of AD, by Sex, Ages ≥60 Years, N, 2018
  • Figure 13: 8MM, Total Prevalent Cases of AD by Age, Both Sexes, N, 2018
  • Figure 14: 8MM, Total Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, N, 2018
  • Figure 15: 8MM, Diagnosed Prevalent Cases of AD, Both Sexes, Ages ≥60 Years, N, 2018
  • Figure 16: 8MM, Diagnosed Prevalent Cases of AD, by Sex, Ages ≥60 Years, N, 2018
  • Figure 17: 8MM, Diagnosed Prevalent Cases of AD by Age, Both Sexes, N, 2018
  • Figure 18: 8MM, Diagnosed Prevalent Cases of AD by Severity, Both Sexes, Ages ≥60 Years, N, 2018
  • Figure 19: 8MM, Total Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years
  • Figure 20: 8MM, Total Prevalent Cases of MCI, by Sex, Ages ≥60 Years, N, 2018
  • Figure 21: 8MM, Total Prevalent Cases of MCI by Age, Both Sexes, N, 2018
  • Figure 22: 8MM, Diagnosed Prevalent Cases of MCI, Both Sexes, Ages ≥60 Years
  • Figure 23: 8MM, Diagnosed Prevalent Cases of MCI, by Sex, Ages ≥60 Years, N, 2018
  • Figure 24: 8MM, Diagnosed Prevalent Cases of MCI by Age, Both Sexes, N, 2018
  • Figure 25: Disease Management Timeline For Alzheimer's Disease
  • Figure 26: Unmet Need and Opportunity in AD, 2020
  • Figure 27: Overview of the Development Pipeline in MCI and AD
  • Figure 28: Active Phase II and Phase III Clinical Trials in MCI and AD by Drug Class, 2020
  • Figure 29: Key Phase II/III and III Trials, Promising Pipeline Agents for MCI and AD, 8MM, 2018-2028
  • Figure 30: Key Phase III Trials of Promising Pipeline Agents for AD-Associated Agitation, 8MM, 2018-2028
  • Figure 31: Competitive Assessment of the Late-Stage Pipeline Agents for MCI and AD, 2018-2028
  • Figure 32: Company Portfolio Gap Analysis in AD, 2018-2028
  • Figure 33: Allergan SWOT Analysis, 2020
  • Figure 34: Lundbeck SWOT Analysis, 2020
  • Figure 35: Eisai SWOT Analysis, 2020
  • Figure 36: Novartis SWOT Analysis, 2020
  • Figure 37: Roche SWOT Analysis, 2020
  • Figure 38: Biogen SWOT Analysis, 2020
  • Figure 39: Eli Lilly SWOT Analysis, 2020
  • Figure 40: Takeda SWOT Analysis, 2020
  • Figure 41: 8MM Sales Forecast by Country for AD, 2018 and 2028
  • Figure 42: Sales Forecast by Class for AD in the US in 2018 and 2028
  • Figure 43: Sales Forecast by Class for AD in the 5EU, 2018 and 2028
  • Figure 44: Sales Forecast by Class for AD in Japan in 2018 and 2028
  • Figure 45: Sales Forecast by Class for AD in China in 2018 and 2028